HomeCompareCBLNY vs ABBV

CBLNY vs ABBV: Dividend Comparison 2026

CBLNY yields 4.23% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CBLNY wins by $2442.31M in total portfolio value· pulled ahead in Year 2
10 years
CBLNY
CBLNY
● Live price
4.23%
Share price
$5.10
Annual div
$0.22
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2442.41M
Annual income
$2,336,327,465.61
Full CBLNY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CBLNY vs ABBV

📍 CBLNY pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCBLNYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CBLNY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CBLNY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CBLNY
Annual income on $10K today (after 15% tax)
$359.62/yr
After 10yr DRIP, annual income (after tax)
$1,985,878,345.77/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CBLNY beats the other by $1,985,857,289.76/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CBLNY + ABBV for your $10,000?

CBLNY: 50%ABBV: 50%
100% ABBV50/50100% CBLNY
Portfolio after 10yr
$1221.26M
Annual income
$1,168,176,118.68/yr
Blended yield
95.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CBLNY
No analyst data
Altman Z
2.6
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CBLNY buys
0
ABBV buys
0
No recent congressional trades found for CBLNY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCBLNYABBV
Forward yield4.23%3.06%
Annual dividend / share$0.22$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$2442.41M$102.3K
Annual income after 10y$2,336,327,465.61$24,771.77
Total dividends collected$2434.86M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CBLNY vs ABBV ($10,000, DRIP)

YearCBLNY PortfolioCBLNY Income/yrABBV PortfolioABBV Income/yrGap
1$11,546$846.16$11,550$430.00$4.00ABBV
2← crossover$14,181$1,826.14$13,472$627.96+$709.00CBLNY
3$19,365$4,192.14$15,906$926.08+$3.5KCBLNY
4$31,422$10,700.74$19,071$1,382.55+$12.4KCBLNY
5$66,075$32,453.71$23,302$2,095.81+$42.8KCBLNY
6$198,261$127,561.06$29,150$3,237.93+$169.1KCBLNY
7$927,567$715,427.77$37,536$5,121.41+$890.0KCBLNY
8$7,248,829$6,256,331.97$50,079$8,338.38+$7.20MCBLNY
9$99,144,099$91,387,852.40$69,753$14,065.80+$99.07MCBLNY
10$2,442,411,652$2,336,327,465.61$102,337$24,771.77+$2442.31MCBLNY

CBLNY vs ABBV: Complete Analysis 2026

CBLNYStock

Mersen SA manufactures and sells electrical power products and advanced materials in France, North America, rest of Europe, the Asia-Pacific, and internationally. It operates through Advanced Materials and Electrical Power segments. The company offers electrical protection and control products, such as IEC and UL/CSA low voltage general purpose fuses and fuse gears, high and medium voltage fuses, and power transfer solutions for rail vehicles, as well as surge protection, lightning protection, and power monitoring solutions; and power management solutions, including high speed fuses, DC protection for electric vehicles and battery, cooling solutions, bus bars, and aluminum electrolytic and film capacitors. It also provides anticorrosion equipment comprising heat exchangers; columns, reactors, and pressure vessels; PTFE or PFA bellows, pipes, elbows, and fittings; graphite bursting discs; corrosion resistant materials; and after-sales and maintenance services, as well as graphite specialties, such as isostatic graphite, carbon insulation, extruded graphite, carbon/carbon composites, silicon carbide, and flexible graphite. In addition, the company offers carbon brushes, brush-holders, brush-rockers and brush gear housings, signal and power transmission systems, rotary joints, current collectors, wheel flange lubrication solutions, carbon dust collection systems, and monitoring solutions, as well as slip, pitch control, and electrical ring assemblies. It serves energy, electronics, transportation, corrosive chemicals, and process industries, as well as other markets comprising building, elevator, ski lifts, defense, HVAC, and outdoor LED lighting markets. The company was formerly known as Groupe Carbone Lorraine SA and changed its name to Mersen SA in 2010. Mersen SA was founded in 1889 and is headquartered in Courbevoie, France.

Full CBLNY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CBLNY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CBLNY vs SCHDCBLNY vs JEPICBLNY vs OCBLNY vs KOCBLNY vs MAINCBLNY vs JNJCBLNY vs MRKCBLNY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.